REG - ReNeuron Group plc - Share Purchases by Directors

ReNeuronAnnouncement

18/04/2019 15:45

RNS Number : 6843W
ReNeuron Group plc
18 April 2019
 


 



18 April 2019


AIM: RENE



 
ReNeuron Group plc
("ReNeuron" or the "Company")
 
Share Purchases by Directors
 
ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, was informed on 18 April 2019 that, on the same day, the following purchases of the Company's ordinary shares of 1p each ("Ordinary Shares") were made by a director of the Company:
 



Name


Title


Number of Ordinary Shares purchased


Total beneficial interest in the Company's Ordinary Shares


Percentage of Company's Total Voting Rights




Professor Sir Chris Evans OBE


Non-executive Director


10,000


254,605


0.802



 
 
ENDS
ENQUIRIES:
 



ReNeuron


+44 (0)20 3819 8400




Olav Hellebø , Chief Executive Officer








Michael Hunt, Chief Financial Officer
 








Buchanan


+44 (0) 20 7466 5000




Mark Court, Sophie Wills, Tilly Abraham
 


















Stifel Nicolaus Europe Limited


+44 (0) 20 7710 7600




Jonathan Senior, Stewart Wallace, Ben Maddison (NOMAD and Joint Broker)
 








Nplus1 Singer Advisory LLP


+44 (0) 20 7496 3000




Aubrey Powell, Mark Taylor (Joint Broker)







 
About ReNeuron
ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off the shelf' stem cell treatments, without the need for immunosuppressive drugs.  The Company's lead clinical-stage candidates are in development for disability as a result of stroke and for the blindness-causing disease, retinitis pigmentosa.  ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that would otherwise be unable to reach their site of action.  ReNeuron's shares are traded on the London AIM market under the symbol RENE.L.  For further information visit www.reneuron.com.
The notifications below, made in accordance with the requirements of the EU Market Abuse Regulation, provide further detail:
 
Notification and public disclosure of transactions by persons discharging managerial



 1 


Details of the person discharging managerial responsibilities / person closely associated




a)


Name


Professor Sir Chris Evans OBE




2


Reason for the notification 




a)


Position/status 


Non-Executive Director




b)


Initial notification /Amendment 


Initial notification




3


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


ReNeuron Group plc




b)


LEI  


2138003TU12CQ5TZO137




4


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted




a)


Description of the financial instrument, type of instrument 
Identification code 


Ordinary Shares 1p
RENE - GB00BF5G6K95




b)


Nature of the transaction 


Purchase of ordinary shares




c)


Price(s) and volume(s)
 





 Price(s) 


Volume(s)




2.287


10,000








d)
 


Aggregated information 


N/A




e)


Date of the transaction 


18 April 2019




f)


Place of the transaction 


London Stock Exchange AIM Market



 
 
 




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHGGUBWCUPBGCR